Trial reportBritish journal of cancer2010
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
Trial report in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00484211 (NGR008), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NGR008: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) Previously Treated With no More Than One Systemic Therapeutic Regimen
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.Hepatology (Baltimore, Md.) · 2013Pooled it
- Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients.British journal of cancer · 2012Trial
- Recent Advances in Augmenting the Therapeutic Efficacy of Peptide-Drug Conjugates.Journal of medicinal chemistry · 2025Review
- Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-α.Pharmaceutics · 2022Review
- Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study.The oncologist · 2020Article
- The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target.Journal of oncology · 2020Review
- The Rational Design of Therapeutic Peptides for Aminopeptidase N using a Substrate-Based Approach.Scientific reports · 2017Article
- The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.Oncoimmunology · 2015Article
- Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF.Clinical & experimental metastasis · 2015Article
- Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2013Review
- A model for cancer-suppressive inflammation.Oncoimmunology · 2012Article
- Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- The use of therapeutic peptides to target and to kill cancer cells.Current medicinal chemistry · 2012Review
- Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2011Article
- Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy.Molecular imagingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is able to selectively bind an aminopeptidase N overexpressed on tumour blood vessels.
methodsTwenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1-3), systemic treatments (52%; range, 1-3) or both (33%) received NGR-hTNF 0.8 microg m(-2) once every 3 weeks. The primary aim of the study was progression-free survival (PFS).
resultsNo grade 3-4 treatment-related toxicities were noted. Common toxicity included mild-to-moderate, short-lived chills (63%). Median PFS was 2.3 months (95% CI: 1.7-2.9). A complete response ongoing after 20 months was observed in a sorafenib-refractory patient and a partial response in a Child-Pugh class-B patient, yielding a response rate of 7%. Six patients (22%) experienced stable disease. The disease control rate (DCR) was 30% and was maintained for a median PFS time of 4.3 months. Median survival was 8.9 months (95% CI: 7.5-10.2). In a subset of 12 sorafenib-resistant patients, the response rate was 8% and the median survival was 9.5 months.
conclusionNGR-hTNF was well tolerated and showed single-agent activity in HCC. Further investigation in HCC is of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.